From L to R: Manifold Bio co-founders Gleb Kuznetsov (CEO), Shane Lofgren (head of BD) and Pierce Ogden (CSO)
July 14, 2022 08:00 AM EDTUpdated July 15, 02:32 PM
Financing
Startups

Pro­tein ther­a­peu­tics biotech us­ing 'pro­tein bar­codes' in drug de­vel­op­ment se­cures new fi­nanc­ing — led by Jeff Hu­ber

Paul Schloesser

Associate Editor

Two years af­ter kick­ing things off with $5.4 mil­lion, a George Church spin­out is re­fill­ing its cof­fers to fu­el its ef­forts tack­ling pro­tein ther­a­peu­tics R …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times